Yes, Vimpat (lacosamide) is a controlled substance. It is classified as a Schedule V drug under the federal Controlled Substances Act, which is the lowest and least restrictive schedule. This means it has a recognized but relatively low potential for abuse compared to drugs in higher schedules.
Why Vimpat Is Schedule V
Most seizure medications are not controlled substances at all, so Vimpat’s classification sometimes catches people off guard. The scheduling stems from clinical studies that examined its abuse potential. In a study of recreational drug users, a supratherapeutic dose of 800 mg (well above the normal range) produced some brief feelings of euphoria, but it also caused significant nausea and a persistent sense of feeling unwell that participants described as “bad drug effects.” When asked whether they would take the drug again, participants rated it no differently than a placebo. A normal therapeutic dose of 200 mg produced effects statistically similar to a sugar pill.
Those findings led the DEA to conclude that lacosamide carries detectable but low abuse potential, enough to warrant placement in Schedule V but not a stricter category. For comparison, cough syrups containing small amounts of codeine also sit in Schedule V.
What Vimpat Treats
Vimpat is FDA-approved to treat partial-onset seizures in patients aged 4 and older. It comes in three forms: film-coated tablets, an oral solution, and an intravenous injection for hospital use. It works differently from older seizure drugs like phenytoin or carbamazepine. While those medications block sodium channels when they fire rapidly, Vimpat selectively enhances a process called slow inactivation of sodium channels. In practical terms, this means it calms overactive neurons involved in seizure activity without broadly suppressing normal brain signaling the same way other sodium-channel drugs do.
What Schedule V Means for Your Prescription
Schedule V is the least restrictive controlled substance category, but it still comes with rules that differ from an ordinary prescription. Here’s what to expect:
- Prescription required. Unlike some Schedule V products that can be dispensed by a pharmacist in certain states, Vimpat always requires a prescription from a licensed provider.
- Refill limits. Federal law allows partial fills for Schedule V prescriptions, but no dispensing can occur more than six months after the prescription was originally written. After that, you need a new prescription.
- Pharmacy handling. Your pharmacist will track Vimpat dispensing the way they would any controlled substance. Some states use prescription drug monitoring programs that log each fill.
- Transferring prescriptions. Moving a controlled substance prescription between pharmacies can involve extra steps. Call your new pharmacy ahead of time if you need to switch.
In day-to-day terms, the Schedule V classification rarely creates major inconveniences. It is far less burdensome than the restrictions placed on Schedule II drugs (like certain stimulants or opioids), which cannot be refilled at all and require a new prescription each time.
Side Effects Related to Its Controlled Status
Because Vimpat has some central nervous system activity, you may notice dizziness, drowsiness, or coordination problems, especially when starting the medication or increasing the dose. At very high doses in study settings, participants reported euphoria alongside nausea and dysphoria, but at standard prescribed doses, those effects were not meaningfully different from placebo. The FDA labeling also carries a class-wide warning about suicidal thoughts that applies to all anti-seizure medications, not just Vimpat specifically.
Physical dependence is a concern with many controlled substances, but Vimpat’s low schedule reflects the limited evidence for withdrawal or drug-seeking behavior at therapeutic doses. That said, stopping any seizure medication abruptly can trigger rebound seizures, so tapering off under medical guidance is standard practice regardless of a drug’s schedule.
How It Compares to Other Seizure Medications
The vast majority of anti-seizure drugs, including levetiracetam, lamotrigine, and carbamazepine, are not scheduled at all. Vimpat is one of the few exceptions. Some older medications like certain barbiturate-based seizure drugs fall into stricter schedules (Schedule IV or even Schedule III). Vimpat sits at the bottom of the controlled substance hierarchy, reflecting the clinical evidence that its abuse potential is real but minimal. If you’re switching from an unscheduled seizure medication to Vimpat, the main practical difference is that your pharmacy may handle the prescription slightly differently, and you may need to plan refills a bit more carefully.